<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26311969</article-id><article-id pub-id-type="pmc">4540866</article-id><article-id pub-id-type="publisher-id">jpts-2015-158</article-id><article-id pub-id-type="doi">10.1589/jpts.27.2293</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Benefits of short-term structured exercise in non-overweight women with
polycystic ovary syndrome: a prospective randomized controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Turan</surname><given-names>Volkan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mutlu</surname><given-names>Ebru Kaya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Solmaz</surname><given-names>Ulas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ekin</surname><given-names>Atalay</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tosun</surname><given-names>Ozge</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tosun</surname><given-names>Gokhan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mat</surname><given-names>Emre</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gezer</surname><given-names>Cenk</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malkoc</surname><given-names>Mehtap</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1)</label> Department of Obstetrics and Gynecology, Tepecik Training
and Research Hospital, Turkey</aff><aff id="aff2"><label>2)</label> Department of Physiotherapy and Rehabilitation, Faculty of
Health Sciences, Istanbul University, Turkey</aff><aff id="aff3"><label>3)</label> Department of Physiotherapy, Dokuz Eylul University,
Turkey</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Atalay Ekin, Department of Obstetrics and Gynecology, Tepecik Training
and Research Hospital: Izmir, Turkey. (E-mail: <email xlink:href="atalayekin@hotmail.com">atalayekin@hotmail.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2015</year></pub-date><volume>27</volume><issue>7</issue><fpage>2293</fpage><lpage>2297</lpage><history><date date-type="received"><day>25</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>2015&#x000a9;by the Society of Physical Therapy Science. Published by IPEC
Inc.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>[Purpose] The short-term effects of structured exercise on the anthropometric,
cardiovascular, and metabolic parameters of non-overweight women diagnosed with polycystic
ovary syndrome were evaluated. [Subjects and Methods] Thirty women with a diagnosis of
polycystic ovary syndrome were prospectively randomized to either a control group (n=16)
or a training group (n=14) for a period of 8 weeks. Anthropometric, cardiovascular, and
metabolic parameters and hormone levels were measured and compared before and after the
intervention. [Results] Waist and hip measurements (anthropometric parameters); diastolic
blood pressure; respiratory rate (cardiovascular parameters); levels of low-density
lipoprotein cholesterol, total cholesterol, fasting glucose, and fasting insulin; and the
homeostasis model assessment of insulin resistance index (metabolic parameters) were
significantly lower in the training group after 8 weeks of exercise compared to the
baseline values. After exercise, the training group had significantly higher oxygen
consumption and high-density lipoprotein levels and significantly shorter menstrual cycle
intervals. The corresponding values for controls did not significantly differ between the
start and end of the 8-week experiment. [Conclusion] Short-term regular exercise programs
can lead to improvements in anthropometric, cardiovascular, and metabolic parameters of
non-overweight women with polycystic ovary syndrome.</p></abstract><kwd-group><title>Key words</title><kwd>Exercise</kwd><kwd>Non-overweight</kwd><kwd>Polycystic ovary syndrome</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Polycystic ovary syndrome (PCOS) occurs in 5&#x02013;10% of women of reproductive age<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. Chronic anovulation, hyperandrogenism, and
insulin resistance are the main characteristics of PCOS<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>. These patients also have elevated triglyceride and low-density
lipoprotein (LDL) cholesterol levels and low high-density lipoprotein (HDL) cholesterol
levels<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>.</p><p>Treatment is generally focused on normalizing anovulation and reducing metabolic syndrome
parameters. Diet and exercise are recommended as first-line treatments by the majority of
gynecologists and endocrinologists. The aim is to reduce abdominal fat, hyperandrogenemia,
and insulin resistance and to improve lipid profiles<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>. Published studies have demonstrated the positive effects of
exercise training on maximal oxygen consumption (MaxVO<sub>2</sub>), weight, and waist
circumferences in PCOS patients<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. Combined
aerobic and resistance exercise is more effective than either aerobic or resistance exercise
alone in improving insulin sensitivity and glycemic control and in reducing abdominal fat in
obese women with PCOS<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>. However, the metabolic and clinical characteristics of PCOS
patients who are not overweight, and thus the efficacy of the various forms of exercise,
have not been evaluated<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. For example, in
overweight PCOS patients, exercise programs lasting 12 weeks tended to yield positive
results<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>, whereas benefits might be achieved more quickly by PCOS patients
who are not overweight.</p><p>We hypothesized that 8 weeks of structured exercise would be sufficient to improve the
anthropometric, cardiovascular, and metabolic parameters of non-overweight women with PCOS,
at least over the short term. Therefore, we conducted a randomized controlled clinical trial
to establish the beneficial effects of exercise on these 3 sets of parameters in
non-overweight PCOS patients.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>We evaluated PCOS patients whose body mass index (BMI) was in the normal range (&#x0003c;
25&#x02005;kg/m<sup>2</sup>) according to the definition of obesity for Asians. All patients were
admitted to our center between March 2011 and May 2014. The study was approved by the Human
Research Ethics Committee of Dokuz Eylul University, Izmir, Turkey (reference no.: 03/38-09,
GOA385). Written informed consent was obtained from all patients. PCOS patients were
diagnosed on the basis of Rotterdam Criteria (2003), which requires the presence of two of
the following:<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup> (1) a polycystic ovary,
defined as the presence of &#x0003e;10 cysts 2&#x02013;8&#x02005;mm in diameter, an ovarian volume
&#x0003e;10&#x02005;cm<sup>3</sup>, and an echodense stroma on transvaginal or pelvic
ultrasonography;<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup> (2) clinical
hyperandrogenism (Ferriman-Gallwey<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>
score &#x0003e;8) or biochemical hyperandrogenism (serum testosterone level &#x0003e;3.6&#x02005;pg/mL in the
absence of other causes of hyperandrogenism); and (3) oligomenorrhea and/or anovulation.</p><p>The following patients were excluded: patients with endocrinological diseases, including
diabetes, thyroid, adrenal, or pituitary gland dysfunction; cardiovascular, hepatic, or
pulmonary disease; a history of orthopedic or other physical symptoms that would otherwise
limit exercise performance; and those who had exercised regularly within the last 6 months.
The resulting 32 non-overweight women with PCOS were randomly allocated into a training
group (n = 16) that participated in a structured exercise program for 8 weeks or a control
group (n = 16) that did not participate in a structured exercise program. The trial flow
chart is shown in <xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Study flow chart</p></caption><graphic xlink:href="jpts-27-2293-g001"/></fig>. Randomization was carried out using a computer-generated random number table and
pre-labeled, sealed envelopes. Based on the results, participants were assigned to one of
the two groups.</p><p>Anthropometric parameters (body mass index, waist, and hip measurements), cardiovascular
parameters (systolic and diastolic blood pressure, heart rate, respiratory rate,
MaxVO<sub>2</sub>), metabolic parameters (HDL cholesterol, LDL cholesterol, triglycerides,
total cholesterol, fasting glucose, fasting insulin, and homeostasis model assessment [HOMA]
insulin resistance index), and hormone levels (follicle stimulating hormone [FSH],
luteinizing hormone [LH], estradiol, total testosterone, and free testosterone) were
measured pre- and post-intervention. The dates of the patients&#x02019; menstrual cycles were also
recorded. All clinical assessments were performed by the same physician.</p><p>Blood samples were obtained between 7:30 a.m. and 8:30 a.m., (after overnight fasting)
during the early follicular phase (days 2&#x02013;5) of a progesterone-induced menstrual cycle.
Blood samples were obtained from supine patients after a 30-min resting period and collected
in tubes containing ethylenediaminetetraacetic acid. The samples were immediately
centrifuged at 4&#x02005;&#x000b0;C for 20&#x02005;min at 1,600&#x02005;g and stored at &#x02212;20&#x02005;&#x000b0;C until assayed. Plasma LH,
FSH, estradiol, and free and total testosterone levels were measured using specific
radioimmunoassay. Blood insulin and glucose levels were measured with a solid-phase
chemiluminescent enzyme immunoassay and the glucose oxidase method, respectively. Insulin
resistance was estimated based on the HOMA index (basal glucose&#x02005;mmol &#x000d7; basal insulin
mIU/mL/22.5).</p><p>Hip and waist circumferences were determined using a tape measure, measuring the widest
circumference of the buttocks and the smallest circumference of the waist. Blood pressure
was measured with a manual sphygmomanometer from a seated patient after a 5-min resting
period. Heart and respiratory rates were evaluated manually. The radial pulse was measured
over a period of 10 s. MaxVO<sub>2</sub> was calculated indirectly during a 6-min walking
test<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup> performed as follows: patients
were given a stopwatch and asked to begin walking on a flat track at their natural walking
speed. At the end of 6&#x02005;min, the walking distance in meters was recorded. Heart rate, blood
pressure, and respiratory rate were recorded before and after the test. The following
formula was used to calculate MaxVO<sub>2</sub> at the end of the 6-min walking test:</p><p>MaxVO<sub>2</sub> = 132.853 &#x02212; (0.0769 &#x000d7; weight) &#x02212; (0.3877 &#x000d7; age) + (6.315 &#x000d7; gender (male:
1, female: 0) &#x02212; (3.2649 &#x000d7; time) &#x02212; (0.1565 &#x000d7; heart rate).</p><p>At the beginning of the study, general dietary and behavioral advice, but not a structured
calorie restriction program, was provided to all study participants. All patients were
counseled regarding a healthy, balanced meal plan with regular food and a nutritional
composition in which 50% of the calories were from carbohydrates, 25% from protein, and 25%
from fat.</p><p>Patients participated in a structured exercise program 3 times per week for 8 weeks at the
Physical Therapy and Rehabilitation Fitness Unit of Dokuz Eylul University. During each
session (50&#x02013;60&#x02005;min), the patients performed aerobic and resistance exercises. Each session
was preceded by a 5-min warm-up and static stretching of the upper and lower limbs, neck,
and trunk muscles, followed by a 5-min cool down. The training sessions were supervised by a
physiotherapist. Weekly physical activity was initially monitored using the International
Physical Activity Questionnaire<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>. The
exercise program included the following: 1. <italic>Warm-up and cool</italic>-<italic>down
exercises:</italic> Walking on a treadmill at a low pace. 2. <italic>Aerobic
exercise:</italic> A step was used for aerobic training. All patients started training
with a 10&#x02005;cm high step. Five weeks later, it was raised to a height of 15&#x02013;20&#x02005;cm. Depending
on the exercise tolerance of the patient, the exercise duration was increased from 5&#x02013;7&#x02005;min
to 20&#x02005;min over the 8 weeks of the study. The exercise was submaximal in intensity. The Borg
Scale was used to rate perceived exertion<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>. Daily exercise was considered 1 session, and the session intensity
was equivalent to 10&#x02013;15 points on the Borg Scale, thus achieving 65&#x02013;70% of the maximum heart
rate according to the American College of Sports Medicine. 3. <italic>Resistance
exercise</italic>: Isoflex exercises utilizing an elastic band targeted the following
muscles: Hip flexors, extensors, abductors, adductors, hamstrings, internal and external
obliques, rectus abdominis, back extensors, scapular, and quadriceps muscles. The
participants performed 15 repetitions of each exercise, with a minimum resting period of
30&#x02005;s and a maximum of 1&#x02005;min between each repetition. Exercise intensity was controlled
individually, with the patient rating the exercise intensity according to a perceived
exertion scale for resistance exercise<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup>.
The patients were advised to maintain an exercise intensity close to 5 or 6, which
corresponded to a perception of &#x0201c;somewhat intense&#x0201d; exercise.</p><p>Statistical tests were performed using the SPSS (Statistical Package for the Social
Sciences for Windows, version 15.0, SPSS, Chicago, IL, USA). The normal distribution of the
variables was determined using the Kolmogorov-Smirnov test. Only the BMI and FSH/LH
variables were distributed normally. Due to the small sample size and multiple non-normally
distributed variables, differences between the training and control groups were assessed
using the Mann-Whitney U test. The pre- and post-intervention values of the groups were
compared using the Wilcoxon signed rank test. The results are presented as the mean &#x000b1;
standard error of the mean. A p value &#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>During the 3&#x02005;year period, 382 patients were identified as having PCOS. Of these, 56
fulfilled the inclusion criteria. The 32 patients who agreed to participate in the study
were divided randomly into groups of 16 patients each. However, two patients in the training
group were eventually excluded because of inadequate attendance (&#x0003c; 75% of the training
sessions). Thus, the study was completed by 14 patients in the training group and 16 in the
control group. All 30 patients fulfilled the Rotterdam Criteria for PCOS: 30 had polycystic
ovaries and anovulation, 26 (86.7%) had clinical hyperandrogenism, and 19 (63.3%) had
biochemical hyperandrogenism. The mean age of the patients was 24.45 &#x000b1; 2.8&#x02005;years (range:
17&#x02013;34&#x02005;years).</p><p>The anthropometric and cardiovascular parameters of the two groups are listed in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Comparison of anthropometric and cardiovascular parameters between and within
groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="3" colspan="1">Variable</th><th colspan="3" valign="middle" align="center" rowspan="1">Training group (n = 14)</th><th colspan="3" valign="middle" align="center" rowspan="1">Control group (n = 16)</th></tr><tr><th colspan="3" rowspan="1"><hr/></th><th colspan="3" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Baseline</th><th valign="top" align="center" rowspan="1" colspan="1">8 w later</th><th valign="top" align="center" rowspan="1" colspan="1">Difference</th><th valign="top" align="center" rowspan="1" colspan="1">Baseline</th><th valign="top" align="center" rowspan="1" colspan="1">8 w later</th><th valign="top" align="center" rowspan="1" colspan="1">Difference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">21.8&#x000b1;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">21.7&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">21.9&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">21.7&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.04&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Waist measurement (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">68.8&#x000b1;2.1</td><td align="center" valign="top" rowspan="1" colspan="1">67.6&#x000b1;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.18&#x000b1;0.4*</td><td align="center" valign="top" rowspan="1" colspan="1">68.4&#x000b1;3.9</td><td align="center" valign="top" rowspan="1" colspan="1">68.6&#x000b1;4.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.31&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hip measurement (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">99.8&#x000b1;4.7</td><td align="center" valign="top" rowspan="1" colspan="1">97.7&#x000b1;4.6</td><td align="center" valign="top" rowspan="1" colspan="1">2.06&#x000b1;0.6*</td><td align="center" valign="top" rowspan="1" colspan="1">100&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">100.1&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.31&#x000b1;0.1**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg) </td><td align="center" valign="top" rowspan="1" colspan="1">120.5&#x000b1;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">117.8&#x000b1;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.5&#x000b1;2.9</td><td align="center" valign="top" rowspan="1" colspan="1">110.6&#x000b1;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">108.1&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x000b1;1.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">75.3&#x000b1;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">72&#x000b1;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.1&#x000b1;3.1*</td><td align="center" valign="top" rowspan="1" colspan="1">70.6&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">67.5&#x000b1;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">3.3&#x000b1;1.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HR (beats/min)</td><td align="center" valign="top" rowspan="1" colspan="1">84.8&#x000b1;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">81.2&#x000b1;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">3.62&#x000b1;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">84.5&#x000b1;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">88.1&#x000b1;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">3.5&#x000b1;1.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RR (breaths/min)</td><td align="center" valign="top" rowspan="1" colspan="1">22.5&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">21.5&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x000b1;0.4*</td><td align="center" valign="top" rowspan="1" colspan="1">21.6&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">21.4&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MaxVO<sub>2</sub> (ml/kg/min)</td><td align="center" valign="top" rowspan="1" colspan="1">587.9&#x000b1;21.7</td><td align="center" valign="top" rowspan="1" colspan="1">664.9&#x000b1;23.1</td><td align="center" valign="top" rowspan="1" colspan="1">76.1&#x000b1;10.8*</td><td align="center" valign="top" rowspan="1" colspan="1">588.3&#x000b1;41.1</td><td align="center" valign="top" rowspan="1" colspan="1">591.7&#x000b1;36</td><td align="center" valign="top" rowspan="1" colspan="1">3.4&#x000b1;1.3**</td></tr></tbody></table><table-wrap-foot><p>Results are presented as the mean &#x000b1; standard error of the mean. *p &#x0003c; 0.05, between
baseline and after exercise values, by Mann-Whitney U test. **p &#x0003c; 0.05, between
difference scores of training and control groups, by Mann-Whitney U test. BMI: body
mass index; DBP: diastolic blood pressure; HR: heart rate; max VO<sub>2</sub>: maximal
oxygen consumption; SBP: systolic blood pressure; RR: respiratory rate</p></table-wrap-foot></table-wrap>, and the metabolic parameters are shown in <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Comparison of hormone levels and metabolic parameters between and within
groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="center" colspan="1">Variable</th><th colspan="3" valign="middle" align="center" rowspan="1">Training group (n = 14)</th><th colspan="3" valign="middle" align="center" rowspan="1">Control group (n = 16)</th></tr><tr><th colspan="3" rowspan="1"><hr/></th><th colspan="3" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Baseline</th><th valign="top" align="center" rowspan="1" colspan="1">8 w later</th><th valign="top" align="center" rowspan="1" colspan="1">Difference</th><th valign="top" align="center" rowspan="1" colspan="1">Baseline</th><th valign="top" align="center" rowspan="1" colspan="1">8 w later</th><th valign="top" align="center" rowspan="1" colspan="1">Difference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FSH (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">5.4&#x000b1;0.23</td><td align="center" valign="top" rowspan="1" colspan="1">5.0&#x000b1;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">5.4&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.04&#x000b1;0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LH (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">7.1&#x000b1;1.5</td><td align="center" valign="top" rowspan="1" colspan="1">8.8&#x000b1;1.57</td><td align="center" valign="top" rowspan="1" colspan="1">1.7&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">12.5&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">12.4&#x000b1;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FSH/LH</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.02&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.0&#x000b1;0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">E<sub>2</sub> (pmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">36.0&#x000b1;8.4</td><td align="center" valign="top" rowspan="1" colspan="1">63.5&#x000b1;14</td><td align="center" valign="top" rowspan="1" colspan="1">27.4&#x000b1;18.5</td><td align="center" valign="top" rowspan="1" colspan="1">56.7&#x000b1;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">56.8&#x000b1;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.12&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total testosterone (nmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000b1;0.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Free testosterone (pg/ml)</td><td align="center" valign="top" rowspan="1" colspan="1">3.15&#x000b1;0.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.15&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.00&#x000b1;0.0</td><td align="center" valign="top" rowspan="1" colspan="1">2.9&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.83&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.10&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL-C (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">44.6&#x000b1;0.63</td><td align="center" valign="top" rowspan="1" colspan="1">45.2&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.6&#x000b1;0.1*</td><td align="center" valign="top" rowspan="1" colspan="1">46.1&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">46.1&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0&#x000b1;0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">122.6&#x000b1;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">114&#x000b1;4.9</td><td align="center" valign="top" rowspan="1" colspan="1">8.62&#x000b1;1.5*</td><td align="center" valign="top" rowspan="1" colspan="1">118.5&#x000b1;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">118.6&#x000b1;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.2**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">141.1&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">138.2&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.8&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">139.6&#x000b1;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">140.5&#x000b1;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.8&#x000b1;0.4**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total Cholesterol (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">198.6&#x000b1;3.7</td><td align="center" valign="top" rowspan="1" colspan="1">195.1&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">3.4&#x000b1;1.1*</td><td align="center" valign="top" rowspan="1" colspan="1">200.5&#x000b1;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">200.7&#x000b1;4.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000b1;0.7**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">98.1&#x000b1;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">93.6&#x000b1;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.4&#x000b1;2.5*</td><td align="center" valign="top" rowspan="1" colspan="1">97.7&#x000b1;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">97.3&#x000b1;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000b1;0.3**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting insulin (&#x003bc;U/ml)</td><td align="center" valign="top" rowspan="1" colspan="1">14.7&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">13.9&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">0.8&#x000b1;0.1*</td><td align="center" valign="top" rowspan="1" colspan="1">14.3&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">14.5&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000b1;0.2**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA index</td><td align="center" valign="top" rowspan="1" colspan="1">3.2&#x000b1;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.9&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.3&#x000b1;0.0*</td><td align="center" valign="top" rowspan="1" colspan="1">3.1&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">3.1&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.1**</td></tr></tbody></table><table-wrap-foot><p>Results are presented as the mean &#x000b1; standard error of mean. *p &#x0003c; 0.05, between
baseline and after exercise values, by Mann-Whitney U test. **p &#x0003c; 0.05, between
difference scores of training and control groups, by Mann-Whitney U test.
E<sub>2</sub>: estradiol; FSH: follicle stimulating hormone; HDL-C: high-density
lipoprotein cholesterol; HOMA: homeostatic model assessment; LDL-C: low-density
lipoprotein cholesterol; LH: luteinizing hormone</p></table-wrap-foot></table-wrap>. Patients in the control and training groups did not significantly differ in
their baseline parameters. In the training group, several anthropometric and cardiovascular
parameters improved significantly after the exercise program; they showed significant
decreases in waist circumference (p = 0.02), hip circumference (p = 0.01), diastolic blood
pressure (p = 0.04), and respiratory rate (p = 0.04) and a significant increase in
MaxVO<sub>2</sub> (p = 0.001). In the control group, anthropometric and cardiovascular
parameters were not significantly different after 8 weeks compared to the baseline values.
The differences in hip circumference (p = 0.04) and MaxVO<sub>2</sub> (p &#x0003c; 0.001) after 8
weeks were significantly higher in the training group than in controls (<xref rid="tbl_001" ref-type="table">Table 1</xref>).</p><p>The changes in hormone levels and metabolic parameters between the two groups are shown in
<xref rid="tbl_002" ref-type="table">Table 2</xref>. In the training group, the decreases
in LDL cholesterol (p &#x0003c; 0.001), total cholesterol (p = 0.01), fasting glucose (p &#x0003c;
0.001), fasting insulin (p = 0.001), and HOMA (p &#x0003c; 0.001) after exercise were
significant, as was the increase in HDL (p = 0.002). In controls, none of the hormonal or
metabolic parameters were significantly different at the end of the study period. The
differences in LDL cholesterol (p = 0.01), HDL (p = 0.05), triglycerides (p = 0.005), total
cholesterol (p = 0.01), fasting glucose (p = 0.01), fasting insulin (p = 0.001), and HOMA
index (p &#x0003c; 0.001) values were significantly greater in the training group than in
controls at the end of the study (<xref rid="tbl_002" ref-type="table">Table 2</xref>). The
mean menstrual cycle interval did not change significantly in the control group (46.12 &#x000b1; 1.3
days vs. 47.05 &#x000b1; 1.2 days, p = 0.125) but decreased significantly in the training group
after exercise (48.09 days vs. 27.3 days, p = 0.04).</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>We investigated the effects of an 8-week structured exercise program on non-overweight
patients with PCOS. Many studies have reported that exercise training has beneficial effects
on cardiopulmonary functional capacity and metabolic syndrome parameters in overweight
patients with PCOS; however, this is the first study to evaluate the benefits of structured
exercise in non-overweight PCOS patients. We found that 8 weeks of structured exercise was
effective for improving anthropometric, cardiovascular, and metabolic parameters and for
regulating menstrual cycles in non-overweight patients with PCOS, despite the absence of
significant changes in sex hormones.</p><p>The beneficial effects of physical fitness are related to its reduction of the risk of
cardiovascular dysfunction and to the delayed onset of metabolic syndrome activity of the
proteins involved in insulin signal transduction in skeletal muscles<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup>. Therefore, by following a systematic exercise program,
PCOS patients can improve their cardiopulmonary functional capacity and insulin sensitivity.
Modalities other than fitness have been suggested for the treatment of PCOS. Fux Otta et
al.<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup> reported the additive effect of
metformin on diet and exercise in the improvement of hyperandrogenism and insulin
resistance. Although some studies have reported additive benefits of insulin
sensitizers<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r22" ref-type="bibr">22</xref><sup>)</sup>, others have not<xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r24" ref-type="bibr">24</xref><sup>)</sup>. In contrast, all studies of PCOS have
found that lifestyle changes should be considered in the management of these patients.
However, there is no consensus on the basic variables of exercise training, including its
type, intensity, duration, frequency, and progression. Orio et al.<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup> evaluated whether the effects of a training program were
maintained after its cessation. They found that 12 weeks of non-training resulted in a
complete loss of all favorable adaptations obtained from the exercise program. Therefore,
exercise may need to be maintained throughout life for its benefits to be preserved.
Although other studies have evaluated the impact of diet on the treatment of PCOS, we found
that structured exercise alone was beneficial, at least in the short-term.</p><p>The role of non-pharmacological therapy in PCOS patients has been evaluated in several
studies. Giallauria et al.<xref rid="r26" ref-type="bibr">26</xref><sup>)</sup> assigned 124
PCOS patients to 2 groups for a 3-month exercise program. They demonstrated that exercise
improved autonomic function and inflammatory patterns. In a similar study (based on 90 young
women with PCOS who were randomly divided into 2 groups<xref rid="r27" ref-type="bibr">27</xref><sup>)</sup>), patients who participated in a 3-month structured exercise
program exhibited improvements in cardiopulmonary functional capacity. Other studies have
reported greater reductions in BMI than our study<xref rid="r28" ref-type="bibr">28</xref><sup>)</sup>, but we did not focus on weight loss, as the patients were not
overweight. Nevertheless, they experienced important changes in several cardiovascular
parameters and in MaxVO<sub>2</sub>.</p><p>Among the PCOS studies in the literature, positive results have been obtained in overweight
patients who exercised for 12&#x02013;24 weeks<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>,<xref rid="r28" ref-type="bibr">28</xref><sup>)</sup>.
Exactly when the beneficial effects of exercise can first be observed has not been
determined. We found that in non-overweight PCOS patients with adequate (&#x02265;75%) participation
in an exercise program consisting of aerobic and resistance exercise, anthropometric,
metabolic, and cardiovascular parameters were already improved after 8 weeks. However,
whether the same effects occur in morbidly obese patients with PCOS or whether they are
apparent after a longer or shorter period of exercise remains to be determined.</p><p>Several studies have reported that diet changes, either alone or in combination with
exercise, resulting in a weight loss of 5&#x02013;10% could restore menstrual cycles. Weight
reduction also has been shown to improve both the reproductive and the metabolic features of
PCOS. Weight loss normalizes ovulation, ameliorates hyperandrogenism, and improves insulin
sensitivity<xref rid="r29" ref-type="bibr">29</xref><sup>)</sup>. In the present study,
structured exercise for 8 weeks was sufficient for non-overweight patients with PCOS to
achieve significant improvements in waist and hip measurements but did not lead to
significant weight loss.</p><p>Our results suggest that an 8-week exercise program improves reproductive and metabolic
disorders related to metabolic syndrome in non-overweight PCOS patients. Long-term regular
exercise may provide better results in metabolic parameters and improve the quality of life
of these patients. The effects of exercise may occur more quickly in non-overweight than in
overweight PCOS patients. The duration of exercise that achieves the maximum benefits may
differ between these two groups of patients and requires further study.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Ehrmann</surname><given-names>DA</given-names></name></person-group>: <article-title>Polycystic ovary syndrome</article-title>. <source>N Engl
J Med</source>, <year>2005</year>, <volume>352</volume>:
<fpage>1223</fpage>&#x02013;<lpage>1236</lpage>. <pub-id pub-id-type="pmid">15788499</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Sheehan</surname><given-names>MT</given-names></name></person-group>: <article-title>Polycystic ovarian syndrome: diagnosis and
management</article-title>. <source>Clin Med Res</source>, <year>2004</year>,
<volume>2</volume>: <fpage>13</fpage>&#x02013;<lpage>27</lpage>. </mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name><name><surname>Papavassiliou</surname><given-names>AG</given-names></name><name><surname>Kandarakis</surname><given-names>SA</given-names></name><etal>et al.</etal></person-group>: <article-title>Pathophysiology and types of dyslipidemia in
PCOS</article-title>. <source>Trends Endocrinol Metab</source>, <year>2007</year>,
<volume>18</volume>: <fpage>280</fpage>&#x02013;<lpage>285</lpage>. </mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Lombard</surname><given-names>CB</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Polycystic ovary syndrome and weight
management</article-title>. <source>Womens Health (Lond Engl)</source>,
<year>2010</year>, <volume>6</volume>: <fpage>271</fpage>&#x02013;<lpage>283</lpage>.
<pub-id pub-id-type="pmid">20187731</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Thomson</surname><given-names>RL</given-names></name><name><surname>Buckley</surname><given-names>JD</given-names></name><name><surname>Noakes</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>The effect of a hypocaloric diet with and without exercise
training on body composition, cardiometabolic risk profile, and reproductive function in
overweight and obese women with polycystic ovary syndrome</article-title>. <source>J
Clin Endocrinol Metab</source>, <year>2008</year>, <volume>93</volume>:
<fpage>3373</fpage>&#x02013;<lpage>3380</lpage>. <pub-id pub-id-type="pmid">18583464</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Heo</surname><given-names>T</given-names></name></person-group>: <article-title>Effects of exercise therapy on blood lipids of obese
women</article-title>. <source>J Phys Ther Sci</source>, <year>2014</year>,
<volume>26</volume>: <fpage>1675</fpage>&#x02013;<lpage>1677</lpage>. <pub-id pub-id-type="pmid">25435675</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>: <article-title>Study of the relationship between exercise therapy and
diet therapy in type 2 diabetes mellitus patients</article-title>. <source>J Phys Ther
Sci</source>, <year>2011</year>, <volume>23</volume>:
<fpage>485</fpage>&#x02013;<lpage>488</lpage>. </mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group>: <article-title>Clinical and metabolic features of polycystic ovary
syndrome among Chinese adolescents</article-title>. <source>J Pediatr Adolesc
Gynecol</source>, <year>2012</year>, <volume>25</volume>:
<fpage>390</fpage>&#x02013;<lpage>395</lpage>. </mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Thomson</surname><given-names>RL</given-names></name><name><surname>Buckley</surname><given-names>JD</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><etal>et al.</etal></person-group>: <article-title>Comparison of aerobic exercise capacity and muscle
strength in overweight women with and without polycystic ovary syndrome</article-title>.
<source>BJOG</source>, <year>2009</year>, <volume>116</volume>:
<fpage>1242</fpage>&#x02013;<lpage>1250</lpage>. <pub-id pub-id-type="pmid">19438498</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><article-title>Rotterdam
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary
syndrome</article-title>. <source>Fertil Steril</source>, <year>2004</year>,
<volume>81</volume>: <fpage>19</fpage>&#x02013;<lpage>25</lpage>. </mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Orio</surname><given-names>F</given-names></name><name><surname>Palomba</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Ovarian size and blood flow in women with polycystic ovary
syndrome and their correlations with endocrine parameters</article-title>.
<source>Fertil Steril</source>, <year>2005</year>, <volume>84</volume>:
<fpage>413</fpage>&#x02013;<lpage>419</lpage>. <pub-id pub-id-type="pmid">16084883</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Ferriman</surname><given-names>D</given-names></name><name><surname>Gallwey</surname><given-names>JD</given-names></name></person-group>: <article-title>Clinical assessment of body hair growth in
women</article-title>. <source>J Clin Endocrinol Metab</source>, <year>1961</year>,
<volume>21</volume>: <fpage>1440</fpage>&#x02013;<lpage>1447</lpage>. <pub-id pub-id-type="pmid">13892577</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Kervio</surname><given-names>G</given-names></name><name><surname>Carre</surname><given-names>F</given-names></name><name><surname>Ville</surname><given-names>NS</given-names></name></person-group>: <article-title>Reliability and intensity of the six-minute walk test in
healthy elderly subjects</article-title>. <source>Med Sci Sports Exerc</source>,
<year>2003</year>, <volume>35</volume>: <fpage>169</fpage>&#x02013;<lpage>174</lpage>.
<pub-id pub-id-type="pmid">12544651</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Saglam</surname><given-names>M</given-names></name><name><surname>Arikan</surname><given-names>H</given-names></name><name><surname>Savci</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>International physical activity questionnaire: reliability
and validity of the Turkish version</article-title>. <source>Percept Mot
Skills</source>, <year>2010</year>, <volume>111</volume>:
<fpage>278</fpage>&#x02013;<lpage>284</lpage>. <pub-id pub-id-type="pmid">21058606</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Borg</surname><given-names>G</given-names></name></person-group>: <article-title>Perceived exertion as an indicator of somatic
stress</article-title>. <source>Scand J Rehabil Med</source>, <year>1970</year>,
<volume>2</volume>: <fpage>92</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="pmid">5523831</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Robertson</surname><given-names>RJ</given-names></name><name><surname>Goss</surname><given-names>FL</given-names></name><name><surname>Rutkowski</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Concurrent validation of the OMNI perceived exertion scale
for resistance exercise</article-title>. <source>Med Sci Sports Exerc</source>,
<year>2003</year>, <volume>35</volume>: <fpage>333</fpage>&#x02013;<lpage>341</lpage>.
<pub-id pub-id-type="pmid">12569225</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jun</surname><given-names>I</given-names></name><name><surname>Ju</surname><given-names>S</given-names></name></person-group>: <article-title>Impact of home exercise training on patients with acute
myocardial infarction</article-title>. <source>J Phys Ther Sci</source>,
<year>2012</year>, <volume>24</volume>: <fpage>743</fpage>&#x02013;<lpage>745</lpage>.
</mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Seo</surname><given-names>BD</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name></person-group>: <article-title>Effect of walking exercise on changes in cardiorespiratory
fitness, metabolic syndrome markers, and high-molecular-weight adiponectin in obese
middle-aged women</article-title>. <source>J Phys Ther Sci</source>, <year>2014</year>,
<volume>26</volume>: <fpage>1723</fpage>&#x02013;<lpage>1727</lpage>. <pub-id pub-id-type="pmid">25435686</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Yagura</surname><given-names>C</given-names></name><name><surname>Takamura</surname><given-names>N</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>: <article-title>Cardiorespiratory fitness and metabolic markers in healthy
young adult men</article-title>. <source>J Phys Ther Sci</source>, <year>2011</year>,
<volume>23</volume>: <fpage>845</fpage>&#x02013;<lpage>849</lpage>. </mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Fux Otta</surname><given-names>C</given-names></name><name><surname>Wior</surname><given-names>M</given-names></name><name><surname>Iraci</surname><given-names>GS</given-names></name><etal>et al.</etal></person-group>: <article-title>Clinical, metabolic, and endocrine parameters in response
to metformin and lifestyle intervention in women with polycystic ovary syndrome: a
randomized, double-blind, and placebo control trial</article-title>. <source>Gynecol
Endocrinol</source>, <year>2010</year>, <volume>26</volume>:
<fpage>173</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="pmid">20148739</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Harborne</surname><given-names>L</given-names></name><name><surname>Fleming</surname><given-names>R</given-names></name><name><surname>Lyall</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>: <article-title>Descriptive review of the evidence for the use of
metformin in polycystic ovary syndrome</article-title>. <source>Lancet</source>,
<year>2003</year>, <volume>361</volume>: <fpage>1894</fpage>&#x02013;<lpage>1901</lpage>.
<pub-id pub-id-type="pmid">12788588</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Nestler</surname><given-names>JE</given-names></name></person-group>: <article-title>Metformin for the treatment of the polycystic ovary
syndrome</article-title>. <source>N Engl J Med</source>, <year>2008</year>,
<volume>358</volume>: <fpage>47</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="pmid">18172174</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>A&#x000e7;bay</surname><given-names>O</given-names></name><name><surname>G&#x000fc;ndo&#x0011f;du</surname><given-names>S</given-names></name></person-group>: <article-title>Can metformin reduce insulin resistance in polycystic
ovary syndrome?</article-title><source>Fertil Steril</source>, <year>1996</year>,
<volume>65</volume>: <fpage>946</fpage>&#x02013;<lpage>949</lpage>. <pub-id pub-id-type="pmid">8612854</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Ehrmann</surname><given-names>DA</given-names></name><name><surname>Cavaghan</surname><given-names>MK</given-names></name><name><surname>Imperial</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of metformin on insulin secretion, insulin action,
and ovarian steroidogenesis in women with polycystic ovary syndrome</article-title>.
<source>J Clin Endocrinol Metab</source>, <year>1997</year>, <volume>82</volume>:
<fpage>524</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="pmid">9024248</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Orio</surname><given-names>F</given-names></name><name><surname>Giallauria</surname><given-names>F</given-names></name><name><surname>Palomba</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Metabolic and cardiopulmonary effects of detraining after
a structured exercise training programme in young PCOS women</article-title>.
<source>Clin Endocrinol (Oxf)</source>, <year>2008</year>, <volume>68</volume>:
<fpage>976</fpage>&#x02013;<lpage>981</lpage>. <pub-id pub-id-type="pmid">17980005</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Giallauria</surname><given-names>F</given-names></name><name><surname>Palomba</surname><given-names>S</given-names></name><name><surname>Maresca</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>: <article-title>Exercise training improves autonomic function and
inflammatory pattern in women with polycystic ovary syndrome (PCOS)</article-title>.
<source>Clin Endocrinol (Oxf)</source>, <year>2008</year>, <volume>69</volume>:
<fpage>792</fpage>&#x02013;<lpage>798</lpage>. <pub-id pub-id-type="pmid">18505468</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Vigorito</surname><given-names>C</given-names></name><name><surname>Giallauria</surname><given-names>F</given-names></name><name><surname>Palomba</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Beneficial effects of a three-month structured exercise
training program on cardiopulmonary functional capacity in young women with polycystic
ovary syndrome</article-title>. <source>J Clin Endocrinol Metab</source>,
<year>2007</year>, <volume>92</volume>: <fpage>1379</fpage>&#x02013;<lpage>1384</lpage>.
<pub-id pub-id-type="pmid">17264174</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Liao</surname><given-names>LM</given-names></name><name><surname>Nesic</surname><given-names>J</given-names></name><name><surname>Chadwick</surname><given-names>PM</given-names></name><etal>et al.</etal></person-group>: <article-title>Exercise and body image distress in overweight and obese
women with polycystic ovary syndrome: a pilot investigation</article-title>.
<source>Gynecol Endocrinol</source>, <year>2008</year>, <volume>24</volume>:
<fpage>555</fpage>&#x02013;<lpage>561</lpage>. <pub-id pub-id-type="pmid">19012098</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Panidis</surname><given-names>D</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Rousso</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>: <article-title>Obesity, weight loss, and the polycystic ovary syndrome:
effect of treatment with diet and orlistat for 24 weeks on insulin resistance and
androgen levels</article-title>. <source>Fertil Steril</source>, <year>2008</year>,
<volume>89</volume>: <fpage>899</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="pmid">17980364</pub-id></mixed-citation></ref></ref-list></back></article>